Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: "Philip Sambrook" Clear advanced filters

  • The risk of experiencing a fracture is lower in men than in women beyond the age of 50 years, but the burden of fractures is, nevertheless, substantial in men. This difference in fracture incidence is likely to be accounted for by differences in bone-related and fall-related factors, which are outlined, along with other data relating to the epidemiology, pathophysiology and treatment options for osteoporosis in men, in this Review.

    • Piet Geusens
    • Philip Sambrook
    • Willem Lems
    Reviews
    Nature Reviews Rheumatology
    Volume: 5, P: 497-504

  • Antiresorptive therapies, such as bisphosphonates, estrogens, selective estrogen receptor modulators, calcitonin and denosumab, are used to increase bone strength in individuals with osteoporosis. However, no single antiresorptive therapy is appropriate for all patients or clearly superior to other therapies. This Review describes the advances in our understanding of antiresorptive therapies and summarizes the benefits and risks associated with various drugs with an antiresorptive effect.

    • Jian Sheng Chen
    • Philip N. Sambrook
    Reviews
    Nature Reviews Endocrinology
    Volume: 8, P: 81-91